A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference

S Samakoglu, L Lisowski, T Budak-Alpdogan… - Nature …, 2006 - nature.com
S Samakoglu, L Lisowski, T Budak-Alpdogan, Y Usachenko, S Acuto, R Di Marzo, A Maggio
Nature biotechnology, 2006nature.com
The application of RNA interference (RNAi) to stem cell–based therapies will require highly
specific and lineage-restricted gene silencing. Here we show the feasibility and therapeutic
potential of coregulating transgene expression and RNAi in hematopoietic stem cells. We
encoded promoterless small-hairpin RNA (shRNA) within the intron of a recombinant γ-
globin gene. Expression of both γ-globin and the lariat-embedded small interfering RNA
(siRNA) was induced upon erythroid differentiation, specifically downregulating the targeted …
Abstract
The application of RNA interference (RNAi) to stem cell–based therapies will require highly specific and lineage-restricted gene silencing. Here we show the feasibility and therapeutic potential of coregulating transgene expression and RNAi in hematopoietic stem cells. We encoded promoterless small-hairpin RNA (shRNA) within the intron of a recombinant γ-globin gene. Expression of both γ-globin and the lariat-embedded small interfering RNA (siRNA) was induced upon erythroid differentiation, specifically downregulating the targeted gene in tissue- and differentiation stage–specific fashion. The position of the shRNA within the intron was critical to concurrently achieve high-level transgene expression, effective siRNA generation and minimal interferon induction. Lentiviral transduction of CD34+ cells from patients with sickle cell anemia led to erythroid-specific expression of the γ-globin transgene and concomitant reduction of endogenous βS transcripts, thus providing proof of principle for therapeutic strategies that require synergistic gene addition and gene silencing in stem cell progeny.
nature.com